Meta-Analysis of Dexmedetomidine on Emergence Agitation and Recovery Profiles in Children after Sevoflurane Anesthesia: Different Administration and Different Dosage

Min Zhu¹, Haiyun Wang¹*, Ai Zhu¹, Kaijun Niu², Guolin Wang¹

¹ Department of Anesthesiology, Tianjin Research Institute of Anesthesiology, Tianjin Medical University General Hospital, Tianjin 300052, China, ² Department of Epidemiology, School of Public Health, Tianjin Medical University, Tianjin 300052, China

* wanghy819@hotmail.com

Abstract

The objective of this article is to evaluate the effect of dexmedetomidine on emergence agitation (EA) and recovery profiles in children after sevoflurane anesthesia and its pharmaco-logical mechanisms. Standard bibliographic databases, including MEDLINE, EMBASE, PsycINFO, Springer and ISI Web of Knowledge, were artificially searched to identify all randomized controlled trials (RCTs) comparing the impact of dexmedetomidine with placebo, fentanyl and midazolam on EA and recovery profiles after sevoflurane anesthesia in post-anesthesia care unit (PACU). Two authors assessed the quality of each study independently in accordance with strict inclusion criteria and extracted data. RevMan 5.0 software was applied for performing statistic analysis. The outcomes analyzed included: 1) incidence of EA, 2) emergence time, 3) time to extubation, 4) incidence of post-operation nausea and vomiting, 5) number of patients requiring an analgesic, and 6) time to discharge from PACU. A total of 1364 patients (696 in the dexmedetomidine group and 668 in the placebo, fentanyl and midazolam group) from 20 prospective RCTs were included in the meta-analysis. Compared with placebo, dexmedetomidine decreased the incidence of EA (risk ratio [RR] 0.37; 95% CI 0.30 to 0.46), incidence of nausea and vomiting (RR 0.57; 95% CI 0.38 to 0.85) and number of patients requiring an analgesic (RR 0.43; 95% CI 0.31 to 0.59). However, dexmedetomidine had a significantly delayed effect on the emergence time (weighted mean differences [WMD] 1.16; 95% CI 0.72 to 1.60), time to extubation (WMD 0.61; 95% CI 0.27 to 0.95), and time to discharge from recovery room (WMD 2.67; 95% CI 0.95 to 4.39). Compared with fentanyl (RR 1.39; 95% CI 0.78 to 2.48) and midazolam (RR 1.12; 95% CI 0.54 to 2.35), dexmedetomidine has no significantly difference on the incidence of EA. However, the analgesia effect of dexmedetomidine on postoperation pain has no significantly statistical differences compared with fentanyl (RR 1.12; 95% CI 0.66 to 1.91), which implied that its analgesia effect might play an important role in decreasing the incident of EA. No evidence of publication bias was observed.
Introduction

Children undergoing elective surgeries such as strabismus, tonsillectomy and outpatient surgeries, especially under sevoflurane anesthesia, often experience emergency agitation (EA) and other uncomfortable symptoms [1,2]. EA is a postoperative negative behavior that may include symptoms such as combative movements, excitability, thrashing, disorientation and inconsolable crying [3]. In addition, it is a troublesome phenomenon that can result in injury to the children themselves or damage to the surgical site, leading to dissatisfaction and anxiety for the parents and requiring extra nursing care, which further increases associated healthcare costs [2]. Some studies found that EA was closely associated with various etiologies such as anxiety, pain, physiologic compromise and anesthetics [4]. Moreover, nausea and vomiting, severe pain, eye opening time and extubation time are also the main factors for discharge from the post-anesthesia care unit (PACU) or hospital, affecting the children’s recovery [5]. Therefore, anesthesiologists aim to reduce the incidence of EA and improve the quality of children’s postoperative condition with the help of various drugs and techniques.

Although different drugs including opioids, benzodiazepines and clonidine, one kind of α2-adrenoreceptor agonists, have been tried in clinic either as a prophylactical measure or treatment, the results have been variable[6–10]. Among which, dexmedetomidine, a highly specific α2-adrenoreceptor agonist (receptor selectivity, \( \alpha_2/\alpha_1 = 1620/1 \)), has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage [11,12]. As the result of it, dexmedetomidine has been administered perioperatively to reduce postoperative negative behaviors such as EA and aggression. However it is notable that several study results remain ambiguous about the effectiveness and safety of dexmedetomidine with regard to children’s postoperative condition [2, 13–31].

Therefore, the aim of this study was to undertake a systematic review of the literature to perform a meta-analysis to determine the influence of dexmedetomidine administration on EA and post-operative recovery profiles in children after sevoflurane anesthesia.

Materials and Methods

Search strategy

The methods of this meta-analysis were performed in accordance with the Cochrane Collaboration criterion. MEDLINE, EMBASE, PsycINFO, Springer and ISI Web of Knowledge were searched for relevant electronic studies of randomized controlled trials (RCTs) published before October 31th, 2014. Hand searching techniques also were used to identify appropriate studies. Moreover, we used the following search terms, dexmedetomidine, children, and EA, and limited the search strategy to English language reports in humans. Articles that met the following criteria were included: 1) randomized and double-blind study design; 2) the intervention was treatment with dexmedetomidine given systemically in any dose during the perioperative period; 3) children undergoing sevoflurane anesthesia experiencing EA and 4) participants had no preoperative cognitive dysfunction, had not undergone neurosurgery and had not received pharmacological intervention which disturbs cognitive function, such as epilepsy drugs.

Data extraction and analysis

All data were extracted by two reviewers (H. Wang and G. Wang) independently reviewing every selection for accuracy and consistency. The following outcome measures were extracted from the retrieved reports in the form of mean data plus standard deviation or dichotomous data: 1) incidence of EA, 2) the emergence time, 3) time to extubation, 4) incidence of post-
operation nausea and vomiting, 5) number of patients requiring an analgesic and 6) time to discharge from recovery room. Moreover, the subgroup analysis was performed: 1) different administration ways, 2) different drug dosage, and 3) different surgery procedures. Meanwhile the effect of dexmedetomidine on the incidence of EA was compared following anesthesia induced with fentanyl and midazolam. Furthermore, the analgesic effect of dexmedetomidine was also compared with that of fentanyl. If the necessary data did not allow inclusion in the meta-analysis, the authors of those papers were contacted directly and asked to release the relevant data. Quality of the included studies was assessed by using the modified Jadad score [32] including four items pertaining to description of randomization, allocation concealment, appropriate blinding, and dropouts or withdrawals. The final selected studies were reviewed by an expert (K. Niu) on statistics to ensure the thoroughness and completeness.

Statistical analysis

Statistical analysis was performed using the Review Manager 5 software. Dichotomous data were analyzed by using the risk ratio (RR) computed using the Mantel Haenszel method (fixed or random models). Continuous outcomes measured on the same scale were expressed as a mean value and standard deviation and were analyzed by using weighted mean differences (WMD). I-square ($I^2$) test was performed to assess the impact of study heterogeneity on the results of the meta-analysis. According to the Cochrane review guidelines, if severe heterogeneity was present at $I^2 >50\%$, the random effect models were chosen, otherwise the fixed effect models were used. Moreover, sensitivity analysis was conducted by deleting each study individually to evaluate the quality and consistency of the results. The funnel plot was used to detect potential publication bias.

Results

Outcomes

The vast majority of the literature search results were excluded due to an inappropriate study design, population, intervention or outcome measure. Subsequently, 20 RCTs were included in this meta-analysis (Fig 1). The characteristic of included studies including intervention, premedication, surgery procedures, anesthesia induction and maintenance of anesthesia were collected (Table 1). Moreover our team workers evaluated the quality of included studies by using Modified Jadad Scores (Table 2). To each analysis, the heterogeneity, the model to pool (random effect or fixed effect), the pooled result, and the P value also were showed (Table 3).

Risk of bias

The funnel plot was applied for assessing publication bias of studies included in the incidence of EA in this meta-analysis. No evident publication bias was obtained through the visual distribution of funnel plot (Fig 2).

Sensitivity analysis

We evaluated the effect of each study on the pooled results by excluding single study sequentially. The result shown that the stability of results had no significant changes (data not shown), which validated the rationality and reliability of our analysis.
Fig 1. Studies eligible for inclusion in meta-analysis.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.
Table 1. Characteristics of included studies.

| Author      | Year | Age (y) | Intervention (No. of patients) | Dexmedetomidine Dose (Time) | Surgery | ASA Pre-medication | Anesthesia Induce | Anesthesia Maintain |
|-------------|------|---------|--------------------------------|-----------------------------|---------|--------------------|-------------------|--------------------|
| Sato M[2]   | 2010 | 1–9     | Dexmedetomidine (39)           | 0.3 μg kg⁻¹ iv over         | same-day surgery or       | III NO             | 8% sevoflurane     | 2–5% sevoflurane   |
|             |      |         |                                | 10 min after induction of   | over-night stay            |                    |                   |                    |
|             |      |         |                                |                             | anesthesia surgery         |                     |                   |                    |
| /Placebo(42)|      |         |                                |                             |                        |                     |                   |                    |
| Chen JY[13]| 2013 | 2–7     | Dexmedetomidine (28)           | 1.0 μg kg⁻¹ iv plus         | elective strabismus       | III NO             | O₂ (F₁O₂ = 1.0)   | 0.4 μg kg⁻¹ iv     |
|             |      |         |                                |                             | surgery                  |                     | 1.0, sevoflurane   | iv imidazole       |
|             |      |         |                                | 2.5 L min⁻¹ O₂              |                         |                     | 1.0, 5L min⁻¹ and | 8% sevoflurane     |
| /Placebo(28)|      |         |                                |                             |                          |                     | 5L min⁻¹ and       |                   |
|             |      |         |                                |                             |                          |                     | 8% sevoflurane     |                   |
| Isik B[14]  | 2006 | 1.5–10  | Dexmedetomidine (21)           | 1.0 μg kg⁻¹ iv after        | MRI                  | III NO             | 8% sevoflurine     | 1.5–2.0% sevoflurane|
|             |      |         |                                |                             | surgery                  |                     |                   |                    |
|             |      |         |                                | 2.5 L min⁻¹ O₂              |                         |                     | 1.5–2.5% sevoflurane|
|             |      |         |                                | 2.5 L min⁻¹ N₂O and        |                         |                     | 2.0 L min⁻¹       |
|             |      |         |                                |                             |                          |                     | N₂O and           |                   |
| /Placebo(21)|      |         |                                |                             |                          |                     | 1.0% N₂O and      | 0.15 mg kg⁻¹      |
| Meng QT[15]| 2012 | 5–14    | Dexmedetomidine (80)           | 0.5 μg kg⁻¹ iv plus         | tonsillectomy            | III 40 μg kg⁻¹     | pro 1.5–2.0 mg kg⁻¹|
|             |      |         |                                |                             | operation                |                      | 2.0 L min⁻¹       |
|             |      |         |                                | 0.2 μg kg⁻¹ h⁻¹             |                         |                      | O₂0.5–2.0%        |
|             |      |         |                                |                             |                          |                      | 1.0 mg kg⁻¹       |
|             |      |         |                                |                             |                          |                      | 1.0 μg kg⁻¹ min⁻¹  |
|             |      |         |                                |                             |                          |                      | iv imidazole and  |                   |
| /Placebo(40)|      |         |                                |                             |                          |                      | 0.15 mg kg⁻¹      |                   |
|             |      |         |                                |                             |                          |                      | remifentanil       |                   |
| Shukry M[16]| 2005 | 1–10    | Dexmedetomidine (23)           | 0.2 μg kg⁻¹ h⁻¹ iv started  | elective outpatient      | III NO             | 8% sevoflurine     | 0.4 mg kg⁻¹ H₂O   |
|             |      |         |                                |                             | surgery                  |                      |                   | 0.15 mg kg⁻¹      |
|             |      |         |                                |                             | surgical procedures      |                      |                   | ventilation        |
| /Placebo(23)|      |         |                                |                             |                          |                      | achieve 40–60 BIS | and fentanyl or   |
|             |      |         |                                |                             |                          |                      |                   | not                |
| /Placebo(30)|      |         |                                |                             |                          |                      |                   | spontaneous       |
| /Placebo(30)|      |         |                                |                             |                          |                      |                   | spontaneous       |
| Ibacache ME| 2004 | 1–10    | Dexmedetomidine (60)           | 0.15 μg kg⁻¹ after          | superficial lower        | NO                 | 50% N₂O and 1%   |
| [17]        |      |         |                                |                             | induction of anesthesia  |                      | sevoflurane       | 8% sevoflurane     |
|             |      |         |                                |                             | abdominal and genital    |                      | end-tidal in      |                   |
| /Placebo(30)|      |         |                                |                             | surgery                  |                      | 50% N₂O          |                   |
| Guler G[18] | 2005 | 3–7     | Dexmedetomidine (30)           | 0.5 μg kg⁻¹ iv before       | adenotonsillectomy       | acetaminophen      | 50% N₂O and 1.5–2.0% in 60% |
|             |      |         |                                | the                        |                         |                      | 15 mg kg⁻¹ oral sevoflurane in 0.2% and 40% O₂ | before induce and spontaneous |
| /Placebo(30)|      |         |                                |                             |                         |                      |                  | ventilation with controlled |
|             |      |         |                                |                             |                          |                      |                   | ventilation       |

(Continued)
| Author          | Year (y) | Age (y) | Intervention (No. of patients) | Dexmedetomidine Dose (Time) | Surgery                          | ASA Pre-medication | Anesthesia Induction | Anesthesia Maintain |
|-----------------|----------|---------|-------------------------------|----------------------------|---------------------------------|---------------------|----------------------|---------------------|
| Xu LL[19]       | 2012     | 3–7     | Dexmedetomidine (30)          | 0.5μg·kg⁻¹ iv over 10 min after induction of anesthesia | vitreoretinal surgery        | III NO              | 8% sevoflurane in O₂ and spontaneous ventilation | remifentani 0.2 |
| Pestieau SR[20] | 2011     | 0.5–6   | Dexmedetomidine (51)          | 1.0μg·kg⁻¹ or 2.0μg·kg⁻¹ by nasal mucosa after induction of anesthesia | BMT                            | III NO              | N₂O/O₂ (2:1) gas mixture and 2–3% sevoflurane inspired | sevoflurane concentration and N₂O/O₂ mixture |
| Kim NY[21]      | 2014     | 1–6     | Dexmedetomidine (20)          | 1.0μg·kg⁻¹ iv plus 0.1μg·kg⁻¹·h⁻¹ | ambulatory surgery             | NO                  | 6–7% sevoflurane in adjust end-tidal | 4 L/min O₂ concentration to achieve 45–50 BIS |
| GF El-Rahmawy[22] | 2013   | 2–6     | Dexmedetomidine (14)          | 2.0μg·kg⁻¹ by fascia iliac compartment block after induction of anesthesia | fracture femur surgery        | III 0.5mg·kg⁻¹·h⁻¹ | 1%–5% increasing sevoflurane 1–1.5 | sevoflurane MAC in 40% |
| OM Asaad[23]    | 2011     | 5–10    | Dexmedetomidine (30)          | 0.15μg·kg⁻¹ iv after induction of anesthesia | elective surgical procedures | NO                  | 100% O₂ and 50% N₂O and 1% end-tidal sevoflurane up to 8% sevoflurane in O₂ with total gas above 5L/min | 70% N₂O in O₂ |
| Saadawy I[24]   | 2009     | 1–6     | Dexmedetomidine (30)          | 1.0μg·kg⁻¹ by caudal block after induction of anesthesia | unilateral inguinal hernia repair /orchidopexy | NO                  | propofol 3–4mg·kg⁻¹ | 0.5–2.0 sevoflurane and 70% N₂O in O₂ | 1 L/min O₂ and anaesthetic |
| He L[25]        | 2013     | 3–7     | Dexmedetomidine (61)          | 0.5μg·kg⁻¹ or 1.0μg·kg⁻¹ iv after LMA insertion | elective minor surgery        | III NO              | 8% sevoflurane in O₂ and via a semiclosed anaesthetic | 1 L/min air |

(Continued)
Incidence of EA

Data extracted from relevant articles indicated that dexmedetomidine compared to placebo significantly decreased the incidence of EA in children undergoing sevoflurane anesthesia (RR 0.37; 95%CI 0.30 to 0.46; Fig 3).

In the subgroup analysis, our study suggested that dexmedetomidine effectively decreased the incidence of EA regardless of the route when administered intravenously (RR 0.36; 95% CI 0.28 to 0.45), intrathecally (RR 0.19; 95% CI 0.06 to 0.60) and mucocutaneously (RR 0.55; 95% CI 0.33 to 0.93) (Fig 4). The same phenomenon was found to be associated with different
surgical procedures (Fig 5) (outpatient surgery: RR 0.32; 95% CI 0.22 to 0.46; ear-nose-throat (E.N.T) surgery: RR 0.47; 95% CI 0.33 to 0.66; selective surgery: RR 0.32; 95% CI 0.21 to 0.49) and drug dosages (Fig 6) (single-dose: RR 0.38; 95% CI 0.29 to 0.48; continuouse-dose: RR 0.35; 95% CI 0.22 to 0.54).

Moreover, there was no significant difference in the incidence of EA among patients anesthetized with dexmedetomidine or fentanyl (RR 1.39; 95% CI 0.78 to 2.48; Fig 7). It should be noted that this conclusion was based on the analysis of only three studies and therefore, should be interpreted with caution.

Meanwhile, compared with midazolam (RR 1.12; 95% CI 0.54 to 2.35; Fig 8), dexmedetomidine had no significant impact on the incidence of EA, although this observation may also be limited by the small number of studies (only three) included in our analysis.

**Emergence Time**

Dexmedetomidine compared to placebo had a delayed effect on emergence time in children undergoing sevoflurane anesthesia (WMD 1.16; 95% CI 0.72 to 1.60; Fig 9).

**Time to Extubation**

Dexmedetomidine compared to placebo increased the time to extubation in children undergoing sevoflurane anesthesia (WMD 0.61; 95% CI 0.27 to 0.95; Fig 10).

**Post-anesthesia Nausea and Vomiting**

Compared to placebo, dexmedetomidine decreased significantly the incidence of the occurrence of post-operative nausea and vomiting in children undergoing sevoflurane anesthesia (RR 0.57; 95% CI 0.38 to 0.85; Fig 11).
Number of Patients Requiring Analgesic

Dexmedetomidine reduced the number of patients requiring analgesic compared to placebo in children undergoing sevoflurane anesthesia (RR 0.43; 95% CI 0.31 to 0.59 Fig 12). More importantly, dexmedetomidine had identical analgesic effects compared with fentanyl (RR 1.12; 95% CI 0.66 to 1.91 Fig 13) for the children under sevoflurane anesthesia. Furthermore, the required dosage of local anesthetics such as bupivacaine was reduced and the analgesia time was prolonged (Fig 13).

Time to Discharge from Recovery Room

Dexmedetomidine compared to placebo increased the time to discharge from the recovery room in children undergoing sevoflurane anesthesia (WMD 5.61; 95% CI 4.28 to 6.94). Unfortunately, severe heterogeneity (I² = 76%) was obtained in this analysis, which was mainly attributed to the study by Chen JY et al [13]. When this trial was excluded, the heterogeneity changed from 76% to 0%, and there was also a significant difference in the time to discharge from the recovery room in favor of dexmedetomidine (WMD 2.67; 95% CI 0.95 to 4.39; Fig 14).

Discussion

Twenty RCTs [2,13–31] were identified to evaluate the effect of EA and recovery profiles associated with dexmedetomidine compared with placebo, fentanyl and midazolam after

---

**Table 3. Statistics information of each analysis.**

| Analysis                          | Heterogeneity | Model of pool | Pooled result       | P value   |
|----------------------------------|---------------|---------------|---------------------|-----------|
| **Dex vs Placebo**               |               |               |                     |           |
| 1. Incidence of EA               | $\chi^2 = 2\%$| Fixed effect  | 95% CI 0.37(0.30, 0.46) | P<0.00001 |
| **Subgroup**                     |               |               |                     |           |
| 1.1 different administration     |               |               |                     |           |
| intravenous                      | $\chi^2 = 0\%$| Fixed effect  | 95% CI 0.36(0.28, 0.45) | P<0.00001 |
| intrathecal                      | $\chi^2 = 0\%$| Fixed effect  | 95% CI 0.19(0.06, 0.60) | P = 0.005 |
| mucocutaneous                    | $\chi^2 = 6\%$| Fixed effect  | 95% CI 0.55(0.33, 0.93) | P = 0.02  |
| 1.2 different surgery procedure  |               |               |                     |           |
| outpatient surgery               | $\chi^2 = 10\%$| Fixed effect  | 95% CI 0.32(0.22, 0.46) | P<0.00001 |
| E.N.T surgery                    | $\chi^2 = 0\%$| Fixed effect  | 95% CI 0.47(0.33, 0.66) | P<0.00001 |
| selective surgery                | $\chi^2 = 15\%$| Fixed effect  | 95% CI 0.32(0.21, 0.49) | P<0.00001 |
| 1.3 bolus or continuous dosage   |               |               |                     |           |
| bolus dosage                     | $\chi^2 = 8\%$| Fixed effect  | 95% CI 0.38(0.29, 0.48) | P<0.00001 |
| continuous dosage                | $\chi^2 = 0\%$| Fixed effect  | 95% CI 0.35(0.22, 0.54) | P<0.00001 |
| 2. Time to eye opening           | $\chi^2 = 0\%$| Fixed effect  | 95% CI 1.27(0.73, 1.82) | P<0.00001 |
| 3. Time to extubation            | $\chi^2 = 26\%$| Fixed effect  | 95% CI 0.61(0.27, 0.95) | P = 0.0004 |
| 4. Incidence of post-operation vomiting | $\chi^2 = 0\%$ | Fixed effect  | 95% CI 0.57(0.38, 0.85) | P<0.006  |
| 5. Number of patients requiring analgesic | $\chi^2 = 0\%$ | Fixed effect  | 95% CI 0.43(0.31, 0.59) | P<0.00001 |
| 6. Time to discharge from PACU   | $\chi^2 = 0\%$| Fixed effect  | 95% CI 2.67(0.95, 4.39) | P = 0.002 |
| **Dex vs Fentanyl**              |               |               |                     |           |
| Incidence of EA                  | $\chi^2 = 0\%$| Fixed effect  | 95% CI 1.39(0.78, 2.48) | P = 0.26  |
| **Dex vs Midazolam**             |               |               |                     |           |
| Incidence of EA                  | $\chi^2 = 3\%$| Fixed effect  | 95% CI 1.12(0.54, 2.35) | P = 0.76  |

Dex: dexmedetomidine; PACU: post-anesthesia care unit

doi:10.1371/journal.pone.0123728.t003
sevoflurane anesthesia in children. Nevertheless, there are no widely accepted assessment scales for the evaluation of EA in children, which led to the use of numerous assessment methods and agitation rating systems [13–34]. In most trials, the Pediatric Anesthesia Emergence Delirium scale (PAED) [35] was used for assessing the incidence of EA. We chose the time point after arrival to the PACU for assessment in this meta-analysis. In addition, we chose the incidence of EA post-sevoflurane anesthesia in children as a primary outcome measures analyzed in the present study. This analysis showed that compared with placebo, dexmedetomidine significantly decreased the incidence of EA in children undergoing sevoflurane anesthesia (RR 0.37; 95% CI 0.30 to 0.46). Zhang et al [36] suggested the effect of intravenous dexmedetomidine in the prevention of EA (RR 0.346; 95% CI 0.263 to 0.453). They also assessed the incidence of PONV from the entrance of PACU to 24 hours after surgery (WMD 4.597; 95% CI -0.080 to 9.275). However in their paper only 7 trials were examined, and they mentioned “when the trials of Gupta et al or Chen et al was removed, the reliability of the test would decreased”. In our paper, we assessed the incidence of PONV with more trials included (8 trials). We found that dexmedetomidine significantly decreased the incidence of occurrence of PONV in children undergoing sevoflurane anesthesia (RR 0.57; 95% CI 0.38 to 0.85). Furthermore, we did subgroup analysis for the different route of dexmedetomidine administration. We found that intrathecal and mucocutaneous administration also both decreased the incidence of EA (intrathecally: RR 0.19; 95% CI 0.06 to 0.60; mucocutaneously: RR 0.55; 95% CI 0.33 to 0.93), which would provide new and appropriate choice for dexmedetomidine administration in
clinical work. This is also the difference between ours and the study of Sun et al [37]. In their study, they calculated the sevoflurane related EA in adenotonsillectomy (RR 0.351; 95% CI 0.033 to 0.422). Moreover, Dahmani et al [38] suggested that the E.N.T surgery is associated with a high incidence of EA. In our paper, we did performed the subgroup analysis on the different surgery procedures including outpatient surgeries, E.N.T. surgeries and selective surgeries, which provide more theoretical foundation for application of dexmedetomidine in clinical different surgeries. We found that dexmedetomidine also effectively prevented the EA associated with outpatient surgery (RR 0.32; 95% CI 0.22 to 0.46), E.N.T surgery (RR 0.47; 95% CI 0.33 to 0.66) and the selective operation (RR 0.32; 95% CI 0.21 to 0.49). This provided a novel strategy and broader application for preventing the occurrence and development of EA in children after sevoflurane anesthesia.

EA is a negative behavior including combative movements, excitability, thrashing, disorientation and inconsolable crying.[2,3]. It not only provides a challenging situation to post-anesthesia care providers but also results in higher rate of postoperative complications such as bleeding from operative sites and disturbing the recovery environment[39]. Early epidemiologic studies reported a 5.3% incidence of EA in postoperative patients [39], with a widely varying incidence of EA in children (10% to 80%) [40]. Although the precise etiology of EA following anesthesia is unknown, the risk factors including preschool age, pain, the use of inhalation anesthesia and otolaryngology procedures may provoke this phenomenon[4,40–42]. Meanwhile, studies found that a high incidence of EA was closely associated with sevoflurane anesthesia, and there has not been well-established prophylaxis and treatment [43–45]. Dexmedetomidine
might be useful for management of post-anesthesia EA [18,21,22]. It is worth noting that the evidence of the effects of dexmedetomidine on EA and recovery profiles is still unclear.

Sevoflurane, an inhalation anesthesia agent, is commonly used in clinic anesthesia with rapid induction and fast recovery due to its low blood/gas partition coefficient (0.68) [46]. For the benefit of weak airway irritation, greater hemodynamic stability, comfortable quality and better cooperation with anesthetists, sevoflurane is popular choice for anesthesia in children.

Fig 4. Forest plot for the effect of different administration ways of dexmedetomidine on the incidence of EA.

doi:10.1371/journal.pone.0123728.g004
However, some studies have found that a high incidence of EA (up to 80%) was associated with sevoflurane in children [44,48]. It is frustrating that the morbidity of sevoflurane-associated EA is not related to either the duration of exposure or dose [43]. Although a high incidence of sevoflurane-associated EA has been assumed to be largely related to rapid awakening, propofol anesthesia revealed rapid emergence properties were associated with a low incidence of EA [48]. Similarly, desflurane exhibited faster recovery than other inhalation agents, and has been found to be associated with a high incidence of EA in pediatric patients, which does not support the advantage of rapid emergence [49]. At present, the underlying mechanism of sevoflurane anesthesia-associated EA remains unclear. Further studies are necessary to determine the most effective way to manage EA in order to improve peri-operative outcome in pediatric patients.
Fig 6. Forest plot for the effects of bolus or continuous-dosage administration of dexmedetomidine on the incidence of EA.

doi:10.1371/journal.pone.0123728.g006

Dexmedetomidine and Emergence Agitation and Recovery Profiles

Fig 7. Forest plot for the incidence of EA. The plot displays the study, sample size, weighted risk ratio (RR), confidence interval (CI), and P value. Meta-analysis indicates dexmedetomidine had no difference on the incidence of EA compared with fentanyl. The square shown for each study (first author and year of publication) is the RR for individual trials, and the corresponding horizontal line is the 95% CI. The diamond is the pooled RR with the CI. The different sizes of squares indicate the weight the individual trials had in the analysis, taking into account sample size.

doi:10.1371/journal.pone.0123728.g007
Due to its pharmacologically unique profile, dexmedetomidine can produce stage 2 non-rapid eye movement sleep through activation of the endogenous sleep-promoting pathway, thereby inducing conscious sedation so that patients are drowsy but cooperative and aroused [50,51]. Meanwhile, dexmedetomidine can also produce its analgesic effect via receptors in the spinal cord and attenuate the stress response without evident respiratory depression [52]. In addition, because of the short half-life, about 1.5 to 3 hours, and lack of respiratory side effects, dexmedetomidine is usually superior to other hypnotics and barbiturates [53]. Therefore, based upon these characteristics dexmedetomidine, the pharmacologically active dextro-isomer of medetomidine [4,54], is extensively applied in clinic, especially for sedation and analgesia in pediatric patients [55,56]. Our analysis suggests that compared with midazolam, dexmedetomidine has no significant effect on the incidence of EA, although this conclusion is limited by the small number of studies (n = 3) (RR 1.12; 95% CI 0.54 to 2.35) and further research is required for confirmation. However, in terms of sedation score or anxiety score, dexmedetomidine had identical effects compared to midazolam [31]. It should be noted that dexmedetomidine decreased the side-effects induced by midazolam, such as delayed recovery.
time including the time to eye opening, verbal response and cooperation [57]. However, midazolam produced inferior postoperative analgesia compared with dexmedetomidine [31], indicating that dexmedetomidine is a better choice of sedation for pediatric patients.

Analgesia, one of main pharmacological properties of dexmedetomidine, is deemed to play an important role in preventing EA after inhalation anesthesia. Some studies found that although pain alone could not cause EA [58,59], inadequate postoperative pain control may be closely associated with varying differences in the incidence of EA [60,61], therefore it is one of major causes of the increased frequency and severity of EA [6,62]. For children, it is too difficult to describe pain objectively, therefore various pain assessment tools such as the visual analogue scale (VAS) [63] and the objective pain scale (OPS) [64] were to compare the number of

| Study or Subgroup | dexmedetomidine | placebo | Mean Difference | Mean Difference |
|-------------------|----------------|---------|----------------|----------------|
|                   | Mean    | SD     | Total | Mean    | SD     | Total | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Ali MA, 2013      | 7.47    | 2.1    | 40    | 7.2     | 2.3    | 40    | 12.3%   | 0.27 [-0.70, 1.24] |
| Chen JY, 2013     | 1.5     | 1.3    | 27    | 1.3     | 0.9    | 24    | 30.9%   | 0.20 [-0.41, 0.81] |
| Erdil F, 2009     | 8.5     | 3.6    | 30    | 9.5     | 3.8    | 30    | 3.3%    | -1.00 [-2.87, 0.87] |
| Guler G, 2005     | 5.03    | 2.3    | 30    | 3.3     | 1.3    | 30    | 12.8%   | 1.73 [0.78, 2.68] |
| Gupta N, 2013     | 9.7     | 2.8    | 18    | 9.2     | 2.6    | 18    | 3.7%    | 0.50 [-1.27, 2.27] |
| Isik B, 2006      | 2.5     | 1.3    | 21    | 1.6     | 0.7    | 21    | 28.7%   | 0.90 [0.27, 1.53] |
| Lili X, 2012      | 5.78    | 2.62   | 30    | 5.27    | 3.08   | 30    | 5.5%    | 0.51 [-0.94, 1.96] |
| Meng QT, 2012     | 15.6    | 11.2   | 40    | 14.3    | 8.2    | 40    | 0.6%    | 1.30 [-3.00, 5.60] |
| Meng QT, 2012     | 16.3    | 10.6   | 40    | 14.3    | 8.2    | 40    | 0.7%    | 2.00 [-2.15, 6.15] |
| Shukry M, 2005    | 10.3    | 4.4    | 23    | 10.4    | 4.9    | 23    | 1.6%    | -0.10 [-2.79, 2.59] |

Total (95% CI) 299 296 100.0% 0.61 [0.27, 0.95]

Heterogeneity: Chi² = 12.09, df = 9 (P = 0.21); I² = 26% 
Test for overall effect: Z = 3.52 (P = 0.0004)

Fig 10. Forest plot for time to extubation. The plot displays the study, sample size, weighted mean differences (WMD), confidence interval, and P value. Meta-analysis indicates dexmedetomidine significantly increased the time to extubation compared with the placebo group. The square shown for each study (first author and year of publication) is the mean difference for individual trials, and the corresponding horizontal line is the 95% CI. The diamond is the pooled WMD with the CI. The different sizes of squares indicate the weight the individual trials had in the analysis, taking into account sample size and standard deviations.

doi:10.1371/journal.pone.0123728.g010

| Study or Subgroup | dexmedetomidine | placebo | Risk Ratio | Risk Ratio |
|-------------------|----------------|---------|------------|------------|
|                   | Events | Total | Events | Total | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Ali MA, 2013      | 4      | 40    | 3      | 40    | 6.3% | 1.33 [0.32, 5.58] |
| Chen JY, 2013     | 4      | 27    | 11     | 24    | 24.5% | 0.32 [0.12, 0.88] |
| Erdil F, 2009     | 1      | 30    | 1      | 30    | 2.1% | 1.00 [0.07, 15.26] |
| Guler G, 2005     | 11     | 30    | 16     | 30    | 33.7% | 0.69 [0.39, 1.22] |
| Gupta N, 2013     | 2      | 18    | 9      | 18    | 18.9% | 0.22 [0.06, 0.89] |
| Isik B, 2006      | 1      | 21    | 2      | 21    | 4.2% | 0.50 [0.05, 5.61] |
| Saadawy I, 2009   | 1      | 30    | 2      | 30    | 4.2% | 0.50 [0.05, 5.22] |
| Sato M, 2010      | 3      | 39    | 3      | 42    | 6.1% | 1.08 [0.23, 5.02] |

Total (95% CI) 235 235 100.0% 0.57 [0.38, 0.85]

Total events 27 47
Heterogeneity: Chi² = 5.62, df = 7 (P = 0.58); I² = 0% 
Test for overall effect: Z = 2.74 (P = 0.006)

Fig 11. Forest plot for the number of patients with post-operative nausea and vomiting. The plot displays the study, sample size, weighted risk ratio (RR), confidence interval (CI), and P value. Meta-analysis indicates dexmedetomidine significantly decrease the number of patients with post-operation nausea and vomiting compared with the placebo group. The square shown for each study (first author and year of publication) is the RR for individual trials, and the corresponding horizontal line is the 95% CI. The diamond is the pooled RR with the CI. The different sizes of squares indicate the weight the individual trials had in the analysis, taking into account sample size.

doi:10.1371/journal.pone.0123728.g011
patients who needed post-anesthesia pain control. The results of this meta-analysis suggested that dexmedetomidine could significantly decrease the number of patients requiring post-anesthesia rescue analgesia (RR 0.43; 95% CI 0.31 to 0.59), which might be partly responsible for decreasing the incidence of EA. However, our analysis revealed that there was no significant difference in the incidence of EA induced by dexmedetomidine and fentanyl (RR 1.39; 95% CI 0.78 to 2.48). Although our analysis is subject to limitation by the small number of studies included (only three), the results may provide the basis of a new strategy for reducing postoperative pain in that compared with fentanyl, dexmedetomidine provided superior analgesia (RR 1.12; 95% CI 0.66 to 1.91). In addition to avoiding side-effects such as respiratory depression...
induced by opioid analgesics, dexmedetomidine significantly prolonged the duration of analgesia and decreased the total consumption of rescue analgesic compared with the use of local anesthetics alone [24]. Consequently, due to superior analgesia and fewer side-effects, dexmedetomidine is implicated as a substitute for opioid analgesics for pediatric patients.

Opioids are widely used for analgesia peri- and post-operatively. However, the adverse effects of opioids including emesis, excessive sedation and risk of respiratory depression restrict their clinical application [7]. Moreover the nausea and vomiting caused by opioids affects the recovery quality of children, and produces an intense environment for post-anesthesia care providers [3–5]. In our analysis, dexmedetomidine significantly decreased the number of patients with nausea and vomiting compared with placebo (RR 0.57; 95% CI 0.38 to 0.85). Therefore, the low incidence of nausea and vomiting might provide an advantage, by decreasing the risk of airway obstruction and increasing post-operation safety.

Some studies indicate that rapid emergence from anesthesia, especially inhalation anesthesia, might be a possible cause of EA [6]. In our analysis, dexmedetomidine significantly increased emergence time (WMD 1.16; 95% CI 0.72 to 1.60) and extubation time (WMD 0.61; 95% CI 0.27 to 0.95) in children undergoing sevoflurane anesthesia in PACU. This might be due to the excessive sedation associated with dexmedetomidine, and contribute to the decreased incidence of EA post-anesthesia. However, time to discharge from PACU in the dexmedetomidine group was also significantly increased compared with the placebo group in our study (WMD 2.67; 95% CI 0.95 to 4.39). The new measurement which could reverse such adverse effects of dexmedetomidine should be the focus of future research.

The shortcomings of this meta-analysis are as follows: 1) some outcome measures data, such as agitation scores and pain scores, which were not normally distributed and were reported in the form of median and quartile, and therefore could not be included in the meta-analysis; 2) only English language reports have been included and consequently we may have missing data from important studies published in other languages.

**Conclusion**

From this meta-analysis it is reasonable to conclude that according to the currently available data, intra-operative administration of dexmedetomidine statistically decreased the incidence of EA and postoperative pain in children undergoing sevoflurane anesthesia. Unlike opioids,
which are associated with respiratory depression, dexmedetomidine could prove to have safer sedative and analgesic effects. Meanwhile, dexmedetomidine decreased the number of patients with vomiting, which might be an advantage for airway safety. However, compared with placebo, there was a significant increase in emergence time, time to extubation and discharge from recovery room. Further research is necessary to examine the proper dose, timing and period of dexmedetomidine infusion which could overcome the high incidence of EA induced by sevoflurane anesthesia in pediatrics with shorter emergence.

Supporting Information

S1 PRISMA Checklist. PRISMA Checklist.

Author Contributions

Conceived and designed the experiments: HW GW. Performed the experiments: MZ AZ. Analyzed the data: MZ KN. Wrote the paper: MZ HW.

References

1. Uysal HY, Takmaz SA, Yaman F, Baltaci B, Basar H. The efficacy of intravenous paracetamol versus tramadol for postoperative analgesia after adenotonsillectomy in children. J Clin Anesth. 2011; 23: 53–57. doi:10.1016/j.jclinane.2010.07.001 PMID: 21296248
2. Sato M, Shirakami G, Tazuke-Nishimura M, Matsuura S, Tanimoto K, Fukuda K. Effect of single-dose dexmedetomidine on emergence agitation and recovery profiles after sevoflurane anesthesia in pediatric ambulatory surgery. J Anesth. 2010; 24: 673–682. doi:10.1007/s00540-010-0876-4 PMID: 20585813
3. Mountain BW, Smithson L, Cramolini M, Wyatt TH, Newman M. Dexmedetomidine as a pediatric anesthetic premedication to reduce anxiety and to deter emergence delirium. AANA J. 2011; 79: 219–224. PMID: 21751690
4. Voepel-Lewis T, Burke C, Hadden SM, Tait AR, Malviya S. Nurses’ diagnoses and treatment decisions regarding care of the agitated child. J Perianesth Nurs. 2005; 20: 239–248. PMID: 16102704
5. Moir MS, Bair E, Shinnick P, Messner A. Acetaminophen versus acetaminophen with codeine after pediatric tonsillectomy. Laryngoscope. 2000; 110: 1824–1827. PMID:11081593
6. Galinkin JL, Fazi LM, Cuy RM, Chiavacci RM, Kurth CD, Shah UK, et al. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology. 2000; 93: 1378–1383. PMID:11149429
7. Cohen IT, Finkel JC, Hannallah RS, Hummer KA, Patel KM. The effect of fentanyl on the emergence characteristics after desflurane or sevoflurane anesthesia in children. Anesth Analg. 2000; 94: 1178–1181.
8. Viitanen H, Annila P, Viitanen M, Tarkkila P. Premedication with midazolam delays recovery after ambulatory sevoflurane anesthesia in children. Anesth Analg. 1999; 89: 75–79. PMID:10389782
9. Bock M, Kunz P, Schreckenberger R, Graf BM, Martin E, Motch J. Comparison of caudal and intravenous clonidine in the prevention of agitation after sevoflurane in children. Br J Anaesth. 2002; 88: 790–796. PMID:12173195
10. Patel A, Davidson M, Tran MC, Quraishi H, Schoenberg C, Sant M, et al. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenotonsillectomy. Anesth Analg. 2010; 111: 1004–1010. doi:10.1213/ANE.0b013e3181ee82fa PMID:20705788
11. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesia. Pediatr Crit Care Med. 2007; 8: 115–131. PMID:17273114
12. Arain SR, Ruehlow RM, Uhrich TD, Ebert TJ. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg. 2004; 98: 153–158. PMID:14693611
13. Chen JY, Jia JE, Liu TJ, Qin MJ, Li WX. Comparison of the effects of dexmedetomidine, ketamine, and placebo on emergence agitation after strabismus surgery in children. Can J Anaesth. 2013; 60: 385–392. doi:10.1007/s12301-013-9886-x PMID:23944921
14. Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth. 2006; 16: 748–753. PMID: 16879517

15. Meng QT, Xia ZY, Luo T, Wu Y, Tang LH, Zhao B, et al. Dexmedetomidine reduces emergence agitation after tonsillectomy in children by sevoflurane anesthesia: a case-control study. Int J Pediatr Otorhinolaryngol. 2012; 76: 1036–1041. doi: 10.1016/j.ijporl.2012.03.028 PMID: 22537843

16. Shukry M, Clyde MC, Kalarickal PL, Ramadhyani U. Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia? Paediatr Anaesth. 2005; 15: 1098–1104. PMID: 16324031

17. Ibacache ME, Munoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. Anesth Analg. 2004; 98: 60–63. PMID: 14693585

18. Guler G, Akin A, Tosun Z, Ors S, Esmaoglu A, Boyaci A. Single-dose dexmedetomidine reduces agitation and provides smooth extubation after pediatric adenotonsillectomy. Paediatr Anaesth. 2005; 15: 762–766. PMID: 16101707

19. Lili X, Jianjun S, Haiyan Z. The application of dexmedetomidine in children undergoing vitreoretinal surgery. J Anesth. 2012; 26: 556–561. doi: 10.1007/s00540-012-1354-1 PMID: 22415678

20. Pestieau SR, Quezado ZM, Johnson YJ, Anderson JL, Cheng YI, McCarter RJ, et al. The effect of dexmedetomidine during myringotomy and pressure-equalizing tube placement in children. Paediatr Anaesth. 2011; 21: 1128–1135. doi: 10.1111/j.1460-9592.2011.03615.x PMID: 21575102

21. Kim NY, Kim SY, Yoon HJ, Kil HK. Effect of dexmedetomidine on sevoflurane requirements and emergence agitation in children undergoing ambulatory surgery. Yonsei Med J. 2014; 55: 209–215. doi: 10.3349/ymj.2014.55.1.209 PMID: 24339309

22. El-Rahmawy GF, Hayes SMS. Efficacy of dexmedetomidine addition to bupivacaine on the quality of blind fascia iliaca compartment block in children undergoing femur fracture surgery. Egyptian Journal of Anaesthesia. 2013; 29: 137–142.

23. Asaad OM, Hafez M, Mohamed MY, El-mahgoup SS. Comparative study between prophylactic single dose of fentanyl and dexmedetomidine in the management of agitation after sevoflurane anesthesia in children. Egyptian Journal of Anaesthesia. 2011; 27: 31–37.

24. Saadawy I, Boker A, Elshahawy MA, Almazrooa A, Melibary S, Abdellatif AA, et al. Effect of dexmedetomidine on the characteristics of bupivacaine in a caudal block in pediatrics. Acta Anaesthesiol Scand. 2009; 53: 251–256. doi: 10.1111/j.1399-6576.2008.01818.x PMID: 19076110

25. Ozcengiz D, Gunes Y, Ozmete O. Oral melatonin, dexmedetomidine, and midazolam for prevention of postoperative agitation in children. J Anesth. 2011; 25: 184–188. doi: 10.1007/s00540-011-1099-2 PMID: 21327805

26. Ali MA, Abdellatif AA. Prevention of sevoflurane related emergence agitation in children undergoing adenotonsillectomy: A comparison of dexmedetomidine and propofol. Saudi J Anaesth. 2013; 7: 296–300. doi: 10.4103/1658-354X.115363 PMID: 24015133

27. Mountain BW, Smithson L, Cramolini M, Wyatt TH, Newman M. Dexmedetomidine as a pediatric anesthetic premedication to reduce anxiety and deter emergence delirium. AANA J. 2011; 79(3):219–224. PMID: 21751690

28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaqhan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1–12. PMID: 8721797

29. Cravero JP, Beach M, Dodge CP, Whalen K. Emergence characteristics of sevoflurane compared to halothane in pediatric patients undergoing bilateral pressure equalization tube insertion. J Clin Anesth. 2000; 12: 397–401. PMID: 11025242
34. Cravero J, Surgenor S, Whalen K. Emergence agitation in paediatric patients after sevoflurane analgesia and no surgery: a comparison with halothane. Paediatr Anaesth. 2000; 10: 419–424. PMID: 10886700
35. Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. Anesthesiology. 2004; 100: 1138–1145. PMID: 15114210
36. Zhang C, Hu J, Liu X, Yan J. Effects of intravenous dexmedetomidine on emergence agitation in children under sevoflurane anesthesia: a meta-analysis of randomized controlled trials. PLoS One. 2014; 9(6): e99718. doi: 10.1371/journal.pone.0099718 PMID: 24932765
37. Sun L, Guo R, Sun L. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand. 2014; 58(6):642–650. doi: 10.1111/aas.12292 PMID: 24588393
38. Dahmani S, Delivet H, Hilly J. Emergence delirum in children: an update. Curr Opin Anaesthesiol. 2014; 27(3): 309–315. doi: 10.1097/ACO.0000000000000076 PMID: 24784918
39. Voepel-Lewis T, Malviya S, Tait AR. A prospective cohort study of emergence agitation in the pediatric postanaesthesia care unit. Anesth Analg. 2003; 96: 1625–1630. PMID:12760985
40. Keaney A, Diviney D, Harte S, Lyons B. Postoperative behavioral changes following anesthesia with sevoflurane. Paediatr Anaesth. 2004; 14: 866–870. PMID:15385017
41. Cohen IT, Drewsen S, Hannallah RS. Propofol or midazolam do not reduce the incidence of emergence agitation associated with desflurane anesthesia in children undergoing adenotonsillectomy. Paediatr Anaesth. 2002. 12: 604–609. PMID:12358656
42. Vlajkovic GP, Sindjelic RP. Emergence delirium in children: many questions, few answers. Anesth Analg. 2007; 104: 84–91. PMID: 17179249
43. Jurgens S. Sevoflurane conscious sedation for MRI scanning. Anaesthesia. 2003; 58: 296–297. PMID:12603482
44. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976; 73: 2424–2428. PMID:1065897
45. Ihmsen H, Saanti TI. [Dexmedetomidine. Pharmacokinetics and pharmacodynamics]. Anaesthesist. 2012; 61: 1059–1066. doi: 10.1007/s00101-012-2114-1 PMID: 23223843
46. Tobias JD, Berkenbosch JW. Initial experience with dexmedetomidine in paediatric-aged patients. Paediatr Anaesth. 2002; 12: 171–175. PMID: 11882231
47. Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J. 2004; 97: 451–455. PMID: 15180019
48. Korkusiz M, Ucar N, Acar E, Yndi F. Dexmedetomidine-ketamine and midazolam-ketamine combinations for sedation in pediatric patients undergoing extracorporeal shock wave lithotripsy.
58. Cravero JP, Beach M, Thy B, Whalen K. The effect of small dose fentanyl on the emergence characteristics of pediatric patients after sevoflurane anesthesia without surgery. Anesth Analg. 2003; 97: 364–367. PMID: 12873918

59. Weldon BC, Bell M, Craddock T. The effect of caudal analgesia on emergence agitation in children after sevoflurane versus halothane anesthesia. Anesth Analg. 2004; 98: 321–326. PMID: 14742362

60. Hamunen K, Kontinen V. Systematic review on analgesics given for pain following tonsillectomy in children. Pain. 2005; 117: 40–50. PMID: 16109456

61. Lalićević S, Djordjević I. Comparison of benzydamine hydrochloride and Salvia officinalis as an adjuvant local treatment to systemic nonsteroidal anti-inflammatory drug in controlling pain after tonsillectomy, adenoidectomy, or both: an open-label, single-blind, randomized clinical trial. Current therapeutic research. 2004; 65: 360–372. doi:10.1016/j.curtheres.2004.07.002 PMID: 24672091

62. Watcha MF, Ramirez-Ruiz M, White PF, Jones MB, Lagueruela RG, Terkonda RP. Perioperative effects of oral ketorolac and acetaminophen in children undergoing bilateral myringotomy. Can J Anaesth. 1992; 39: 649–654. PMID: 1394752

63. Hannallah RS, Broadman LM, Belman AB, Abramowitz MD, Epstein BS. Comparison of caudal and ilioinguinal/iliohypogastric nerve blocks for control of post-orchiopexy pain in pediatric ambulatory surgery. Anesthesiology. 1987; 66: 832–834. PMID: 2884900

64. Twersky RS. New modalities in outpatient postoperative pain management. J Clin Anesth. 1993; 5: 57S–63S. PMID: 8292371